CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 139 enrolled
Drug / intervention
Octreotide Long Acting Release +1 moredrug
Likely dose
Octreotide Long Acting Release 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00582426
NCT00582426Phase 3Completed
CompareCT.gov

LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Novartis Pharmaceuticals·interventional·Posted Dec 28, 2007·Updated May 4, 2015

In Brief

A Phase 3 clinical trial evaluating Octreotide Long Acting Release and Standard Treatment for Chemotherapy-induced Diarrhea. Completed, enrolled 139 participants across 11 sites.

Detailed Summary

This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Diarrhea
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2007
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.5 years ago

Interventions

Octreotide Long Acting Releasedrug

Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.

Standard Treatmentother

Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.